↓ Skip to main content

Dove Medical Press

Article Metrics

Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model

Overview of attention for article published in International Journal of Nanomedicine, November 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter
1 tweeter
patent
2 patents

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
39 Mendeley
Title
Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model
Published in
International Journal of Nanomedicine, November 2017
DOI 10.2147/ijn.s149235
Pubmed ID
Authors

Yang Du, Ting Sun, Xiaolong Liang, Yuan Li, Zhengyu Jin, Huadan Xue, Yihong Wan, Jie Tian

Abstract

An intraoperative technique to accurately identify microscopic tumor residuals could decrease the risk of positive surgical margins. Several lines of evidence support the expression and immunotherapeutic effect of PD-1 in breast cancer. Here, we sought to develop a fluorescence-labeled PD-1 probe for in vivo breast tumor imaging and image-guided surgery. The efficacy of PD-1 monoclonal antibody (PD-1 mAb) as adjuvant immunotherapy after surgery was also assessed. PD-1-IRDye800CW was developed and examined for its application in tumor imaging and image-guided tumor resection in an immunocompetent 4T1 mouse tumor model. Fluorescence molecular imaging was performed to monitor probe biodistribution and intraoperative imaging. Bioluminescence imaging was performed to monitor tumor growth and evaluate postsurgical tumor residuals, recurrences, and metastases. The PD-1-IRDye800CW exhibited a specific signal at the tumor region compared with the IgG control. Furthermore, PD-1-IRDye800CW-guided surgery combined with PD-1 adjuvant immunotherapy inhibited tumor regrowth and microtumor metastases and thus improved survival rate. Our study demonstrates the feasibility of using PD-1-IRDye800CW for breast tumor imaging and image-guided tumor resection. Moreover, PD-1 mAb adjuvant immunotherapy reduces cancer recurrences and metastases emanating from tumor residuals.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 38%
Student > Master 6 15%
Researcher 5 13%
Student > Bachelor 2 5%
Unspecified 1 3%
Other 2 5%
Unknown 8 21%
Readers by discipline Count As %
Medicine and Dentistry 9 23%
Biochemistry, Genetics and Molecular Biology 5 13%
Agricultural and Biological Sciences 4 10%
Immunology and Microbiology 4 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Other 5 13%
Unknown 9 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 July 2020.
All research outputs
#3,806,037
of 21,217,760 outputs
Outputs from International Journal of Nanomedicine
#258
of 3,547 outputs
Outputs of similar age
#97,717
of 443,090 outputs
Outputs of similar age from International Journal of Nanomedicine
#13
of 109 outputs
Altmetric has tracked 21,217,760 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,547 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,090 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 109 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.